These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 34812901)

  • 41. [Are psychedelics fast acting antidepressant agents?].
    Gründer G; Brand M; Kärtner L; Scharf D; Schmitz C; Spangemacher M; Mertens LJ
    Nervenarzt; 2022 Mar; 93(3):254-262. PubMed ID: 35103814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.
    Kelly DF; Heinzerling K; Sharma A; Gowrinathan S; Sergi K; Mallari RJ
    Neurosurgery; 2023 Apr; 92(4):680-694. PubMed ID: 36512813
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
    Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
    J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Psychedelics as Medicines: An Emerging New Paradigm.
    Nichols DE; Johnson MW; Nichols CD
    Clin Pharmacol Ther; 2017 Feb; 101(2):209-219. PubMed ID: 28019026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Psychedelics in the treatment of unipolar and bipolar depression.
    Bosch OG; Halm S; Seifritz E
    Int J Bipolar Disord; 2022 Jul; 10(1):18. PubMed ID: 35788817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
    Ko K; Kopra EI; Cleare AJ; Rucker JJ
    J Affect Disord; 2023 Feb; 322():194-204. PubMed ID: 36209780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Towards an understanding of psychedelic-induced neuroplasticity.
    Calder AE; Hasler G
    Neuropsychopharmacology; 2023 Jan; 48(1):104-112. PubMed ID: 36123427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Emerging Field of Psychedelic Psychotherapy.
    Barber GS; Aaronson ST
    Curr Psychiatry Rep; 2022 Oct; 24(10):583-590. PubMed ID: 36129571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
    Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are psychedelics the answer to chronic pain: A review of current literature.
    Kooijman NI; Willegers T; Reuser A; Mulleners WM; Kramers C; Vissers KCP; van der Wal SEI
    Pain Pract; 2023 Apr; 23(4):447-458. PubMed ID: 36597700
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.
    Luoma JB; Chwyl C; Bathje GJ; Davis AK; Lancelotta R
    J Psychoactive Drugs; 2020; 52(4):289-299. PubMed ID: 32529966
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.
    Dos Santos RG; Bouso JC; Hallak JEC
    BMC Psychiatry; 2019 Oct; 19(1):321. PubMed ID: 31660905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reviewing the Potential of Psychedelics for the Treatment of PTSD.
    Krediet E; Bostoen T; Breeksema J; van Schagen A; Passie T; Vermetten E
    Int J Neuropsychopharmacol; 2020 Jun; 23(6):385-400. PubMed ID: 32170326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustained effects of single doses of classical psychedelics in humans.
    Knudsen GM
    Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Potential of Psychedelics for End of Life and Palliative Care.
    Yaden DB; Nayak SM; Gukasyan N; Anderson BT; Griffiths RR
    Curr Top Behav Neurosci; 2022; 56():169-184. PubMed ID: 34958455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.